Literature DB >> 1381808

Prevalence of hepatitis C virus infections in dialysis patients and their contacts using a second generation enzymed-linked immunosorbent assay.

U Schlipköter1, U Gladziwa, K Cholmakov, A Weise, R Rasshofer, B Lorbeer, N Luz, F Deinhardt, M Roggendorf.   

Abstract

The prevalence of antibodies to the hepatitis C virus (HCV) was determined in 498 hemodialysis patients from three german dialysis units, 121 staff members and 42 family members using an enzyme-linked immunosorbent assay (ELISA) of the second generation which detects antibodies to a structural (C22) and to non-structural (C33c, C100, 5-1-1) recombinant antigens to HCV. Using the second generation ELISA 115 patients (23.1%) were anti-HCV positive versus 77 (15.5%) when sera were tested by an ELISA of the first generation containing only a non-structural antigen (C100). In 34 of these 40 discordant sera antibodies against at least one viral protein was found by a recombinant immunoblot assay. Of 5 sera containing antibodies to only one viral protein (C22) 3 were HCV RNA positive by polymerase chain reaction. Epidemiological evaluation of the patients revealed that the prevalence of anti-HCV was correlated to the duration of dialysis but not to the number of blood transfusions. Of 121 staff members 2 (1.6%) and 2 of 42 family members (4.7%) were positive indicating a low risk of the patients' contacts of acquiring HCV infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381808     DOI: 10.1007/bf00202057

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  10 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

Review 2.  The hepatitis C virus and its relationship to the clinical spectrum of NANB hepatitis.

Authors:  H J Alter
Journal:  J Gastroenterol Hepatol       Date:  1990       Impact factor: 4.029

3.  Intrafamilial transmission of hepatitis C virus.

Authors:  G Idéo; G Bellati; E Pedraglio; R Bottelli; T Donzelli; G Putignano
Journal:  Lancet       Date:  1990-02-10       Impact factor: 79.321

4.  Hepatitis C virus antibody.

Authors:  P P Mortimer; B J Cohen; P A Litton; E M Vandervelde; M F Bassendine; A M Brind; M H Hambling
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

5.  Antibodies to hepatitis C virus.

Authors:  M Roggendorf; F Deinhardt; R Rasshofer; J Eberle; U Hopf; B Möller; R Zachoval; G Pape; W Schramm; F Rommel
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

6.  Transmission of hepatitis C virus (HCV) from a haemodialysis patient to a medical staff member.

Authors:  U Schlipköter; M Roggendorf; K Cholmakow; A Weise; F Deinhardt
Journal:  Scand J Infect Dis       Date:  1990

7.  Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay.

Authors:  C L Van der Poel; H T Cuypers; H W Reesink; A J Weiner; S Quan; R Di Nello; J J Van Boven; I Winkel; D Mulder-Folkerts; P J Exel-Oehlers
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

8.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

9.  Characterization of nucleotide sequences from European hepatitis C virus isolates.

Authors:  K Fuchs; M Motz; E Schreier; R Zachoval; F Deinhardt; M Roggendorf
Journal:  Gene       Date:  1991-07-22       Impact factor: 3.688

10.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

  10 in total
  4 in total

Review 1.  Hepatitis C infection after blood product transfusion.

Authors:  D A Kelly
Journal:  Arch Dis Child       Date:  1996-11       Impact factor: 3.791

2.  Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients.

Authors:  H Hinrichsen; G Leimenstoll; G Stegen; H Schrader; U R Fölsch; W E Schmidt
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

3.  Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods.

Authors:  P M Schneeberger; I Keur; W van der Vliet; K van Hoek; H Boswijk; A M van Loon; W C van Dijk; R H Kauffmann; W Quint; L J van Doorn
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

4.  Risk factors for hepatitis C virus sero-positivity among haemodialysis patients receiving care at kidney centre in a tertiary health facility in Maiduguri, Nigeria.

Authors:  Ibrahim Ummate; Ballah Akawu Denue; Ibrahim Musa Kida; Onah Joseph Ohioma; David Bukbuk Baba; Waru Goni
Journal:  Pan Afr Med J       Date:  2014-11-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.